Research progress of copper transporter 1 in platinum-based chemotherapy.
10.11817/j.issn.1672-7347.2018.12.015
- Author:
Qianying OUYANG
1
;
Yujie LIU
1
;
Yingzi LIU
1
Author Information
1. Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008; Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
therapeutic use;
Cation Transport Proteins;
genetics;
metabolism;
Cisplatin;
therapeutic use;
Copper;
Copper Transporter 1;
Drug Resistance, Neoplasm;
genetics;
Platinum;
therapeutic use;
Research;
trends
- From:
Journal of Central South University(Medical Sciences)
2018;43(12):1376-1379
- CountryChina
- Language:Chinese
-
Abstract:
Platinum drugs are widely used in the treatment of various solid tumors, but their resistance to platinum is the most significant obstacle to successful treatment. Copper transporter 1 (CTR1) is the specific transporter for copper, and it mainly locates at the plasma membrane and plays a role in pumping copper into the cell. CTR1 is also the major platinum influx transporter and plays a key role in platinum resistance. The expression, polymorphism, and degradation of CTR1 affect platinum resistance in tumors. Therefore, CTR1 may be a potential predictive biomarker of platinum resistance and a therapeutic target for overcoming platinum resistance.
